Literature DB >> 19158817

Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity.

Moto Kajiwara1, Tomohiro Terada, Ken Ogasawara, Junko Iwano, Toshiya Katsura, Atsushi Fukatsu, Toshio Doi, Ken-ichi Inui.   

Abstract

H(+)/organic cation antiporters (multidrug and toxin extrusion: MATE1 and MATE2-K) play important roles in the renal tubular secretion of cationic drugs. We have recently identified a regulatory single nucleotide polymorphism (SNP) of the MATE1 gene (-32G>A). There is no other information about SNPs of the MATE gene. In this study, we evaluated the functional significance of genetic polymorphisms in MATE1 and MATE2-K. We sequenced all exons of MATE1 and MATE2-K genes in 89 Japanese subjects and identified coding SNPs (cSNPs) encoding MATE1 (V10L, G64D, A310V, D328A and N474S) and MATE2-K (K64N and G211V). All the variants except for MATE1 V10L showed significant decrease in transport activity. In particular, MATE1 G64D and MATE2-K G211V variants completely lost transport activities. When membrane expression level was evaluated by cell surface biotinylation, those of MATE1 (G64D and D328A) and MATE2-K (K64N and G211V) were significantly decreased compared with that of wild type. These findings suggested that the loss of transport activities of the MATE1 G64D and MATE2-K G211V variants were due to the alteration of protein expression in cell surface membranes. This is the first demonstration of functional impairment of the MATE family induced by cSNPs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158817     DOI: 10.1038/jhg.2008.1

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  22 in total

1.  A common 5'-UTR variant in MATE2-K is associated with poor response to metformin.

Authors:  J H Choi; S W Yee; A H Ramirez; K M Morrissey; G H Jang; P J Joski; J A Mefford; S E Hesselson; A Schlessinger; G Jenkins; R A Castro; S J Johns; D Stryke; A Sali; T E Ferrin; J S Witte; P-Y Kwok; D M Roden; R A Wilke; C A McCarty; R L Davis; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2011-09-28       Impact factor: 6.875

2.  Prevention of Cisplatin-Induced Acute Kidney Injury: A Systematic Review and Meta-Analysis.

Authors:  Aghilès Hamroun; Rémi Lenain; Jean Joel Bigna; Elodie Speyer; Linh Bui; Paul Chamley; Nicolas Pottier; Christelle Cauffiez; Edmone Dewaeles; Xavier Dhalluin; Arnaud Scherpereel; Marc Hazzan; Mehdi Maanaoui; François Glowacki
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

3.  Large contiguous gene deletions in Sjögren-Larsson syndrome.

Authors:  Holly Engelstad; Gael Carney; Dana S'aulis; Janae Rise; Warren G Sanger; M Katharine Rudd; Gabriele Richard; Christopher W Carr; Omar A Abdul-Rahman; William B Rizzo
Journal:  Mol Genet Metab       Date:  2011-05-30       Impact factor: 4.797

4.  Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.

Authors:  Hwa Yoon; Hea-Young Cho; Hee-Doo Yoo; Se-Mi Kim; Yong-Bok Lee
Journal:  AAPS J       Date:  2013-02-16       Impact factor: 4.009

5.  Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis.

Authors:  K Toyama; A Yonezawa; S Masuda; R Osawa; M Hosokawa; S Fujimoto; N Inagaki; K Inui; T Katsura
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 6.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 7.  Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics.

Authors:  Atsushi Yonezawa; Ken-ichi Inui
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

Review 8.  Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.

Authors:  Gaia Chiara Mannino; Giorgio Sesti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

Review 9.  Polymorphic transporters and platinum pharmacodynamics.

Authors:  Jason A Sprowl; Rachel A Ness; Alex Sparreboom
Journal:  Drug Metab Pharmacokinet       Date:  2012-09-18       Impact factor: 3.614

Review 10.  An update on the pharmacogenomics of metformin: progress, problems and potential.

Authors:  Jennifer N Todd; Jose C Florez
Journal:  Pharmacogenomics       Date:  2014-03       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.